Fulltext present in this item

Thumbnail
Fulltext: 48318.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: [Antithrombotic therapy during percutaneous coronary interventions]
Author(s): Verheugt, F.W.A. ; Dieker, H.J. ; Aengevaeren, W.R.M.
Publication year: 2005
Source: Nederlands Tijdschrift voor Geneeskunde, vol. 149, iss. 17, (2005), pp. 912-916
ISSN: 0028-2162
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/48318   https://hdl.handle.net/2066/48318

Display more details
Title alternative: [Antithrombotic therapy during percutaneous coronary interventions]
Subject: NCEBP 14: Cardiovascular diseases
UMCN 2.1: Heart, lung and circulation
Organization: Cardiology
Journal title:
Nederlands Tijdschrift voor Geneeskunde
Volume: vol. 149
Issue: iss. 17
Page start: p. 912
Page end: p. 916
Abstract:
Antithrombotic therapy is essential during percutaneous coronary interventions for the prevention of peri-procedural death and myocardial infarction. The most commonly used agents are aspirin, clopidogrel and heparin in patients treated by percutaneous angioplasty or receiving an arterial stent. Glycoprotein IIb/IIIa receptor antagonists such as abciximab are indicated during percutaneous interventions in high-risk-patients as well as, in principle, in all patients with an acute coronary syndrome with ST-segment elevation undergoing primary percutaneous angioplasty. In patients with so-called drug-eluting stents, clopidogrel should be continued for several months longer than the usual 30 days.

This item appears in the following Collection(s)

Browse

Statistics